AstraZeneca’s FORXIGA™ Now Approved in European Union for Treatment of Type 2 Diabetes

FORXIGA is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments.

Read more

Posted in Type II Drugs Glucose & Insulin